Press
Successful exit for High-Tech GrĂźnderfonds: Fagron acquires HiperScan
High-Tech GrĂźnderfonds invested in technology company HiperScan, a spin-off of the Fraunhofer Institute for Photonic Microsystems, shortly after its founding in 2008Dresden-based HiperScan has established itself as the market leader for raw material identification in German pharmaciesBecoming part of Fagron will help accelerate the international establishment of HiperScan’s technology and promote the adoption of personalized medicine
Bonn, 27 April 2022 â Fagron, a leading gl
Press
Alentis Therapeutics closes $105 million Series C funding to advance transformational medicines for Claudin-1
Proceeds will fund:
Clinical programs ALE.F02 and ALE.C04 â two first-in-class anti-Claudin-1Â (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors
The platform to engineer CLDN1 antibody drug conjugates (ADC) and bispecific antibodies
Basel, Switzerland â 13 April 2023, Alentis Therapeutics (âAlentisâ), the Claudin-1 (CLDN1) company, is a clinical-stage biotech company developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Today, A
Press
High-Tech GrĂźnderfonds investing into nfon AGâs telecommunication solution
nfon AG, developer of hosted PBX solutions and provider of integrated communication solutions wins High-Tech GrĂźnderfonds as a lead investor. The patent pending technology and its integration into a coherent marketing concept convinces High-Tech GrĂźnderfonds of the investment.
Jens Blomeyer, Director of Marketing at nfon AG comments âafter a successful market launch, the planned investments into further extension of the platform and its usability will help us to extend our technical advanta
Daniel Wall – Controller
Daniel Wall completed his bachelor’s degree in economics at HHU in DĂźsseldorf at the end of 2021 and immediately afterwards started his master’s degree in business administration – also at HHU.
He has gone through several stations as a working student. From serial purchasing in an industrial group, facultative property insurance in the reinsurance sector, to controlling in an internal shared service center.
In his last position as a working student, he was promoted to “IT Service Controller” after a few months and was commercially responsible for Group-wide IT Service Controlling for almost a year and a half.
His hobbies include sport, especially badminton, and woodworking.
Portfolio
akirolabs
akirolabs, founded in 2021 by Michael Pleuger, Detlef Schultz, Christoph FlĂśthmann, and Tim Ergenzinger, develops and provides an AI powered SaaS platform for collaborative strategic procurement. akirolabs is based upon a world-class and industry proven strategic procurement process, methodology and toolkit, embedded into an intuitive cross-functional collaboration workflow and enriched with all relevant internal and external business insight. akirolabsâ unique approach delivers âProcuremen
Press
MEET YOUR REALITY: HTGF invests in VR startup R3DT
Virtual Reality (VR) software for industrial engineering suitable for everyday use
Virtual prototypes can now be reviewed with bare hands at the push of a button
High-Tech GrĂźnderfonds III as lead investor in the seed financing round
R3DT is CyberLab alumnus and spin-off from the KIT in Karlsruhe
Germany's largest seed investor High-Tech GrĂźnderfonds (HTGF) has acquired a stake in Virtual Reality (VR) start-up R3DT GmbH. The young company from Karlsruhe develops and s
Press
Easily improving efficiency: SOTA SOLUTIONS receives seed investment
Software which creates itself and increases profit â this is the successful concept of SOTA SOLUTIONS, which convinced investors in the early stage. The High-Tech GrĂźnderfonds together with the Gundlach Group supports the start-up from Berlin as investors to enter the market of biochemistry and biogas.
SOTA SOLUTIONS develops software which enables to predict and improve complex processes. Those processes can be steps in the biochemistryâs production as well as controlling biogas facilit
Press
Altavo concludes Series A for the development of its Artificial Voice
February 20, 2024 – Altavo, a startup in AI-based voice rehabilitation founded in 2021, successfully closed its Series A financing round on February 1, 2024. A European consortium led by OCCIDENT is investing ⏠5.0m in the development of Altavoâs novel Artificial Voice.
Altavoâs Artificial Voice is a medical device designed to help voiceless people, for example after laryngectomy or during mechanical ventilation, regain their own, natural sounding voice. The proprietary âsil
Press
Abalos Therapeutics Launches with âŹ12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer
Abalos Therapeutics announced today a EUR 12 million Series A financing round establishing its operations and leadership. The Companyâs objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating a strong anti-tumor immune response. The Series A round was co-led by Boehringer Ingelheim Venture Fund (BIVF) and Gruenderfonds Ruhr, with participation from NRW.BANK and High-Tech GrĂźnde
Press
nfon investors go for growth
The investors in the Munich company nfon AG, one of the leading providers of outsourced telephone systems (IP Centrex), have decided together with nfonâs management to commit additional capital to accelerate growth against the backdrop of this yearâs positive business performance.
The investors High-Tech GrĂźnderfonds, Earlybird Venture Capital GmbH & Co. KG, MIG Fonds and Bayerische Beteiligungsgesellschaft have, in a further round of financing, made four million euros of capital ava
Blog
Built on a firm belief: The greentech node.energy
âTo achieve success, you need perseverance.â Itâs a phrase you might hear in the world of professional sport, but itâs also true for entrepreneurs, says Matthias Karger. The former professional volleyball player is now Co-Founder and Managing Director of HTGF portfolio company node.energy. The greentechâs software-as-a-service solution helps companies with their own wind turbines and solar panels to keep on top of their administrative duties and get the most out of their power gene
Blog
Challenges and highlights of 2020 and an outlook for 2021
Overall, 2020 was a successful year for High-Tech GrĂźnderfonds despite the difficult circumstances. And the seed investor just recently signed off on the best exit in its history. Managing Director Alex von Frankenberg takes a look back at the challenges and highlights of this past year and provides an outlook for 2021.
Alex, congratulations are in order! In summer, your portfolio company MYR received conditional market approval in Europe for the first-ever drug to treat hepatitis&n
Blog
âWe had to scale up the scaling process itselfâ: An interview with BioNTechâs Dr Oliver Hennig
How do you develop, test and produce a vaccine within an extremely short space of time to combat a disease that little is known about? BioNTech knows the answer. Dr Oliver Hennig, Senior Vice President Operations, is a part of this success story. At HTGFâs High-Tech Partnering Conference (HTPC) on 12 April 2022, heâll be talking about his experiences during the past months. In this interview, Dr Hennig explains how he and his team went about planning and implementing the production and d
Press
Spacing rules in the brain: Novel compounds that act as molecular spacers in the brain prevent neurodegeneration
High-Tech GrĂźnderfonds (HTGF) provides seed funding for the neuro start-up FundaMental Pharma GmbH (FMP), a spin-off of the Interdisciplinary Center for Neuroscience (IZN) at Heidelberg University. FMP scientists have discovered a “death complex” in neurons whose activation leads to neurodegeneration. With the identification of a novel class of drugs, the FMP has also laid the foundation for successfully combating life-threatening neurological diseases. The financing makes it no
How passion and expertise led to a billion-euro exit
As a High-Tech Grßnderfonds (HTGF) partner, Dr. Bernd Goergen has signed the most successful exit in HTGF history to date. US pharmaceutical company Gilead Sciences acquired German biotech start-up MYR for roughly EUR 1.15 billion at the end of 2020. In this interview, he speaks about the fight against Hepatitis D, drug development and his own personal successes.
In 2011, HTGF took up a stake in MYR. And in 2020 the billion-euro deal took place. And yet youâve said that there wa
Blog
Quo vadis e-fuels? The road ahead for alternative fuels
What role will e-fuels play for the drivetrains of tomorrow? Itâs a topic that is being talked about more and more in politics and across society â sometimes in a highly emotional way. After all, many believe that the use of alternative drivetrains hinges on a fundamental question: Will we ever be able to move away from the principle of using combustion engines?
The discussion at the start of the year was an important one, as it shone a spotlight on the important topic of e-fuels an